Sage Therapeutics stock drops
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial.
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease.
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre-Market
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) failed to meet the primary goal. The company's shares were down more than 12 percent in pre-market.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
Sage Gemini faces sexual assault allegations
FierceBiotech21h
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
BioSpace20h
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Commercial Observer21h
Sage Realty’s Jonathan Kaufman Iger Wants to Build an Office Brand
The Manhattan owner's inspiration comes from hospitality giants such as Four Seasons and Hilton — and, yes, WeWork.
Hold Rating on SAGE Therapeutics Amid Clinical Trial Uncertainties
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...
Sage stock slides as RBC cuts rating to Sell on trial results concerns
RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to ...
ITWeb2d
ATKV transforms operations with Sage Intacct
The implementation has reduced ATKV's month-end reporting time, enhanced financial transparency and allowed teams to access ...
7News Miami2d
Saving Sage Animal Rescue brings 82 cats from Helene-impacted North Carolina to South Florida shelters
Dozens of cats who were in harm’s way have been saved from danger, thanks to a South Florida animal rescue organization.Volunteers<a class="excerpt-read-more" href=" More ...
Racism charge over Caitlin Clark eye poke question ridiculous: Sage Steele
( NewsNation) — Former ESPN anchor Sage Steele tells “Dan Abrams Live” that Christine Brennan was doing her job when she ...